The Expression And Significance Of IL-17D And CD163in Epithelial Ovarian Tumor

Objective: This study aims to detect the expression of IL-17D,CD163in10cases of normal ovarian tissue and60cases of ovarian epithelial tumorstissue, provide a theoretical basis for the diagnosis, treatment and pathogenesisof epithelial ovarian tumors.Methods:1. Used immunohistochemistry (IHC) S-P method to detecte the expressionof IL-17D, CD163in50cases of epithelial ovarian cancer and10cases ofepithelial ovarian benign tumor,10normal ovarian tissue.2. Statistical analysis: All data uses the SPSS13.0software for statisticalanalysis, The results of immunohistochemistry was used the χ2test and theKruskal-Wallis H Test, two-sided test, the correlation of two factors wasused Spearman rank correlation analysis, with p≤0.05indicated that thedifference is significant in the statistically, with p≤0.01indicated thatthe difference is very significant in statistically.Results：1.The expression of IL-17D and CD163in normal ovarian tissue andovarian epithelial tumors tissueImmunohistochemistry results showed that:The positive expression rate of IL-17D and CD163protein in epithelialovarian cancer group (74.0%,80.0%),was both significantly higher than inepithelial ovarian benign tumor group (40.0%,30.0%) and normal ovariantissue group (0.0%,10.0%), the difference was statistically significant (P<0.01);The positive expression rate of IL-17D and CD163in epithelial ovarianbenign tumor group and the normal ovarian group was both no statisticallydifferent (P>0.05). 2.The expression of IL-17D and CD163protein in epithelial ovarian cancerand the relationship between them and clinical parametersIn different clinical stages:the positive expression rate of IL-17D in late (Ⅲ,Ⅳperiod) epithelial ovarian cancer was74.0%,the positive expression rate ofIL-17D in early (Ⅰ, Ⅱperiod) epithelial ovarian cancer was50.0%,theformer was higher than the latter, the difference was significant in thestatistically(P <0.05);In the different degree of differentiation groups:in the low differentiationgroup, the positive expression rate of IL-17D was90.9%,in the moderate-highdifferentiation group, the positive expression rate was60.7%, the former washigher than the latter, the difference was significant in the statistically(P<0.05);In the different pathological types:the positive expression rate in the serousovarian cancer was66.7%,in the mucinous adenocarcinoma was75.0%,in theendometrial carcinoma was88.9%,in the clear cell carcinoma was40.0%, inthe unclassified adenocarcinoma was80.0%, the difference was not significantin the statistically(P>0.05);I did not find that the expression of IL-17D protein was different betweenthe different age groups (<60years old, the positive expression rate was66.7%;≥60years old, the positive expression rate was63.6%), high and lowgroups of ascites (ascites volume≤500ml, the positive expression rate was66.7%;>500ml, the positive expression rate was79.3%).In different clinical stages:the positive expression rate of CD163in late (Ⅲ,Ⅳ period) epithelial ovarian cancer was88.9%,the positive expression rate ofCD163in early (Ⅰ, Ⅱ period) epithelial ovarian cancer was57.1%,the formerwas higher than the latter, the difference was significant in the statistically(P<0.05);In the different degree of differentiation groups:in the low differentiationgroup, the positive expression rate of CD163was95.5%,in the moderate-highdifferentiation group, the positive expression rate was67.9%, the former washigher than the latter, the difference was significant in the statistically(P <0.05);In the different pathological types:the positive expression rate in the serousovarian cancer was91.7%,in the mucinous adenocarcinoma was50.0%,in theendometrial carcinoma was88.9%,in the clear cell carcinoma was60.0%, inthe unclassified adenocarcinoma was80.0%, the difference was not significantin the statistically(P>0.05);I did not find that the expression of CD163protein was different betweenthe different age groups (<60years old, the positive expression rate was73.3%;≥60years old, the positive expression rate was90.0%), high and lowgroups of ascites (ascites volume≤500ml, the positive expression rate was76.2%;>500ml, the positive expression rate was82.8%).3.The correlation of IL-17D and CD163protein in epithelial ovarian cancertissuesBy detecting, there is a positive correlation between the IL-17D and CD163protein expression at immunohistochemical protein expression level (r=0.388,P=0.005,P<0.05).Conclusion:1. In the normal ovarian tissue, epithelial ovarian benign tumor and epithelialovarian cancer, the positive expression rate of IL-17D and CD163wasgradually increased with increased malignant levels of tumor. It means thatIL-17D and CD163protein may play a role in the occurrence of epithelialovarian cancer.2. The positive expression cases of IL-17D and CD163in epithelial ovariancancer was correlation with the clinical stage and degree of differentiation,with the deepening of clinical stage, the lower differentiation, the positiveexpression cases increased. It means that IL-17D and CD163protein in thedevelopment of epithelial ovarian cancer may play a synergistic andpromote role.3. The expression of IL-17D and CD163has important reference value todiagnosis, determine the degree of malignancy and prognosis the epithelialovarian cancer.